Table 1.
Demographic and clinical features for the 438 participants randomly selected from the ILULU-TB cohort for this study.
| TB, HIV– | TB, HIV+ | LTBI, HIV– | LTBI, HIV+ | OD, HIV– | OD, HIV+ | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CPT | Karonga | CPT | Karonga | CPT | Karonga | CPT | Karonga | CPT | Karonga | CPT | Karonga | |
| Number | 37 | 36 | 37 | 36 | 40 | 33 | 37 | 36 | 38 | 35 | 41 | 32 |
| Age (IQR) | 32·5 (26·5–41·9) | 36 (25·5–53·4) | 33·8 (29–37·9) | 33·2 (28–39·7) | 20·7 (19·3–23·4) | 39 (32·4–51·4) | 31·2 (27·9–35·1) | 44·5 (35·5–49) | 41·2 (29·2–51) | 43·2 (27·5–53·6) | 33·6 (28·6–36·7) | 33·3 (29·4–41·2) |
| Male (n (%)) |
25 (69·4) | 19 (52·8) | 16 (43·2) | 19 (52·8) | 16 (40) | 15 (45·5) | 10 (27) | 9 (25) | 17 (44·7) | 11 (31·4) | 16 (40) | 11 (34·4) |
| CD4+count (IQR) |
n/a | n/a | 170 (69–293) | 168 (45–276)a | n/a | n/a | 345 (231–523) | 312 (246–421) | n/a | n/a | 183 (95–272) | 182 (107–229) |
| On ART (n (%)) |
n/a | n/a | 2 (5·4) | 8 (22·2) | n/a | n/a | 1 (2·7) | 0 (0) | n/a | n/a | 18 (45) | 12 (37·5) |
| BMI (IQR) | 20·4 (18·4–23·6)b | 18·4 (16·6–19·3) | 20·9 (18·6–23·4) | 18·8 (18–20·8) | 23·6 (21·5–28·7) | 22·7 (20·6–23·7) | 24·3 (20·9–27·9) | 21·6 (18·7–23·7) | 22·4 (20·1–23·8)c | 20·8 (19·6–23) | 21·2 (19·8–23·9)d | 19·6 (18·1–21·5) |
These are shown by study site for each of the six clinical groups: active TB (TB), healthy controls with latent TB (LTBI), and unwell patients with other diseases (OD) who initially had TB in their differential diagnosis. The definition of a TB case was culture positivity for Mycobacterium tuberculosis (Mtb). The definition of an OD case was a confirmed other diagnosis plus exclusion of TB. HIV+, HIV infected; HIV–, HIV uninfected; CPT, Cape Town; IQR, interquartile range; ART, antiretroviral therapy; BMI, body mass index; n/a, not applicable. Numbers of missing values were <5 except where indicated by letters a–d (a = 6, b = 5, c = 19, d = 20).